Search

BACKGROUND Meningiomas are common intracranial neoplasms with female predominance and sharply rising incidence in the perimenopausal years. As they often express estrogen receptors, hormone replacement therapy (HRT) poses a theoretical risk inducing accelerated growth. Although HRT has been linked to slightly increased incidence, its actual effect on meningioma growth-rate had not been studied in a clinical population. AIM: We aimed to retrospectively compare tumor characteristics and grow-rates of incidental meningiomas of those with a ≥6-month history of estrogen-based HRT (e-HRT) before or during surveillance compared to those without (no-HRT). METHODS Forty females with e-HRT and 80 age-matched HRT-naïve females were identified from the NorthShore Incidental Meningioma Database. Tumor characteristics and diameters were analyzed on initial and all follow-up MRIs. Progression-free survival (PFS) was assessed. RESULTS Twenty-one patients completed e-HRT before, 10 started before and continued during, and 9 started e-HRT during surveillance. Patient and radiographic characteristics were similar between the groups (mean age 62y in both, parity; tumor calcification, T2W-intensity), whereas those with e-HRT had significantly lower body weight (68±16kg vs. 77±21kg; p=0.01) and tended to have longer follow-up (6.7±3.9yrs vs. 5.3±3.9yrs; p=0.07). Those with e-HRT had significantly smaller meningiomas (13±6mm vs. 16±9mm at diagnosis and 15±7mm vs. 19±11mm at end of follow-up; p=0.03 for both), and slower absolute grow-rates (0.5±0.8 vs 1.0±2.1mm/year; p=0.05) than those of no-HRT. Proportional growth-rate differences were not significant (3.3%/year vs. 5.4%/year p >0.05). Subgroup analyses showed no difference between vaginal vs. oral/subcutaneous/transdermal route e-HRT vs. no-HRT. PFS defined by RECIST1.1, RANO and clinical (new symptoms or treatment) criteria were 11.1, 6.6 and 14.7years in e-HRT versus 10.5, 5.4 and 11.4years in no-HRT. None of the differences were significant (log-rank p >0.1). CONCLUSIONS In this preliminary analysis, those with e-HRT had smaller tumors that grew slower, suggesting that e-HRT may be safe in incidental meningioma.

While recent years have witnessed a steady rise in the number of studies exploring transcranial direct current stimulation (tDCS) as a potential therapy for disorders of the central nervous system, there are to date no FDA approved clinical indications for this form of noninvasive neuromodulation. Successful development of tDCS as an approved therapy in the US and elsewhere will require the implementation of well designed, appropriately powered clinical trials, which, in turn, requires careful consideration of a variety of methodological factors. The choice of study design (e.g. between-subjects, within-subjects) is one the most fundamental decisions in designing a clinical trial. This choice is often influenced by the specific symptoms and natural histories of the disorders being investigated. Disease-related symptoms and disability may influence the design and execution of tDCS trials in other ways, for instance interfering with the ability of patients to participate in studies that involve frequent stimulation sessions in a research setting, or complicating the ability of patients to provide informed consent. Common medical co-morbidities may also influence the efficacy of tDCS as a therapy, either negatively by interfering with the effectiveness of brain stimulation, or positively by providing new treatment targets. The parameters being used to deliver tDCS including stimulation intensity, frequency, and duration, as well as electrode size, number, and location, also play a critical but only partially understood role in tDCS studies. Finally, the use of robust control conditions is an important concern in all clinical trials, including those involving tDCS. This chapter will review these issues as they pertain to the design of tDCS clinical trials, and will conclude with recommendations for the standardization of methods for tDCS clinical trial reporting.

This chapter provides an overview of safety assessment in clinical trials, including challenges for designing and reporting studies measuring safety. Adverse events are undesirable, unfavorable, harmful, and unexpected effects resulting from a normal dosage of drug, medication, therapy, or any other intervention such as surgery. Monitoring of adverse events is critical to the patient’s safety (i.e., human subject’s protection) and data integrity in clinical trials. Moreover, this chapter reviews the regulatory aspects related to adverse events in clinical trials. Finally it presents a case discussion in which an unexpected adverse effect is detected and investigators need to determine whether this event is or is not related to the intervention and define a plan of action.

Chapter 1 explores the history, ethical issues, and importance of regulations in clinical research. The history of clinical research is long and fascinating, starting from dietary therapy, such as legumes and lemons, and advancing to modern-day drugs and regulations. Advances in medical treatments today have been achieved because of the application of knowledge gained from experiments conducted hundreds of years ago. The rules and regulations were required to address unethical issues and the misuse of the clinical research. The chapter asserts that the development of clinical research regulations may still be under development in terms of optimizing safety and the use of future drugs and medical devices.

This chapter discusses the important aspect of changing trial aspects, including analyzing data, before formal completion of a trial. Interim analysis (or analyses before trial is finished) should be planned and described in the study protocol, before starting the trial, to ensure the potential penalties for doing such analyses do not invalidate trial results and/or satisfy ethical requirements. The chapter discusses reasons and methods to perform interim analysis. Based on the results from interim analysis, some adjustments in the trial should be required, including early termination. Although the main goal of adaptive design is to increase the success of clinical development, making the studies more efficient and more likely to demonstrate the effect of a treatment, the investigator needs to be careful when using these methods as they can also introduce other potential biases in the study.

Despite promising preliminary results in treating fibromyalgia (FM) pain, no neuromodulation technique has been adopted in clinical practice because of limited efficacy, low response rate, or poor tolerability. This phase II open-label trial aims to define a methodology for a clinically effective treatment of pain in FM by establishing treatment protocols and screening procedures to maximize efficacy and response rate. High-definition transcranial direct current stimulation (HD-tDCS) provides targeted subthreshold brain stimulation, combining tolerability with specificity. We aimed to establish the number of HD-tDCS sessions required to achieve a 50% FM pain reduction, and to characterize the biometrics of the response, including brain network activation pain scores of contact heat-evoked potentials. We report a clinically significant benefit of a 50% pain reduction in half (n = 7) of the patients (N = 14), with responders and nonresponders alike benefiting from a cumulative effect of treatment, reflected in significant pain reduction ( P = .035) as well as improved quality of life ( P = .001) over time. We also report an aggregate 6-week response rate of 50% of patients and estimate 15 as the median number of HD-tDCS sessions to reach clinically meaningful outcomes. The methodology for a pivotal FM neuromodulation clinical trial with individualized treatment is thus supported. Online Registration Registered in Clinicaltrials.gov under registry number NCT01842009. Perspective In this article, an optimized protocol for the treatment of fibromyalgia pain with targeted subthreshold brain stimulation using high-definition transcranial direct current stimulation is outlined.

BACKGROUND: Meningiomas are among the most common incidental neuroimaging findings. Although most are indolent, a subgroup of meningiomas will eventually warrant clinical intervention. While larger diameters (e.g. ≥2.5cm) predict more aggressive behavior, there is a paucity of data regarding how much surveillance smaller meningiomas require if any. PURPOSE: To assess radiographic features of subcentimeter meningiomas that may predict future progression. METHODS: We included asymptomatic treatment naïve patients with subcentimeter probable meningiomas who had ≥6 months of MRI follow-up. Progression was defined as reaching the 1cm threshold or becoming symptomatic. Imaging characteristics such as presence of calcification, perilesional edema, T2-weighted intensity were assessed in relationship to tendency to progress via log-rank. RESULTS: Thirty-nine patients (mean age 62y, 34F) were identified, who had a total follow-up of 251 years. Twenty-four patients (60%) remained subcentimeter by the end of follow-up. Median time to reach 1cm was 3.0 years for the remaining 15 patients. Only 2 enlarged to 1.5cm, a 69-year-old female who reached this size after 4.5 years and a plateaud on subsequent scans. The other was a 71-year-old male whose tumor doubled about every 3 years, leading to resection after 7 years at 33mm. He harbored a grade 2 meningioma. None of the patients became symptomatic during the follow-up period. None of the patient’s lesions had peritumoral edema. T2W intensity did not predict progression. In contrast, only 1 patient with a calcified meningioma reached 1cm. Calcification predicted slower progression (12.1 vs 6.8 years, log-rank p=0.03). CONCLUSION: Our data corroborates that most subcentimeter meningiomas grow extremely slowly. A single scan confirming calcification in the tumor may further support this growth pattern. However, repeated imaging seems necessary to identify exponential growth pattern, which is associated with higher grade meningiomas that can still present in this population.

Transcranial pulsed current stimulation (tPCS) has been shown to increase inter-hemispheric coherence of brain oscillatory activity, mainly in fronto-temporal regions, leading to enhancement of functional connectivity across neural networks. The question is whether tPCS can modulate behavior significantly. Our aim was to identify the effects of tPCS on paired associative learning task (PALT) and attention switching task (AST), and to further categorize physiological autonomic responses by heart rate variability and electrodermal activity measurements before and after task performance. Thirty healthy volunteers were randomized to receive a single session of sham or active 2 mA tPCS stimulation with a random frequency between 1 and 5 Hz. We show that active tPCS significantly improved response time in the AST compared to sham stimulation, so that subjects who received active tPCS significantly exhibit decreased switching cost between repeat and switch trials. No differences were found in response accuracy on AST and PALT. No significant changes were observed in physiological parameters. Based on our results, we suggest that tPCS has a more pronounced effect on tasks that require the increase of functional connectivity across pre-existent neural circuitry, rather than on tasks that require the development of new learning circuits or the creation of new connections., This research was supported in part by a grant from BrainGear Inc.

Given the recent results provided by previous investigations on transcranial pulsed current stimulation (tPCS) demonstrating its modulatory effects on cortical connectivity; we aimed to explore the application of different random pulsed frequencies. The utility of tPCS as a neuromodulatory technique for cognition performance will come as additional frequency ranges are tested with the purpose to find optimal operational parameters for tPCS. This study was designed to analyze the effects of tPCS using the following random frequencies; 1-5, 6-10, and 11-15 Hz compared with sham on quantitative electroencephalographic changes in the spectral power and interhemispheric coherence of each electroencephalographic frequency band. This was a parallel, randomized, double-blinded, sham-controlled trial. Forty healthy individuals older than 18 years were eligible to participate. The main outcomes were differences in the spectral power analysis and interhemispheric coherence as measured by quantitative electroencephalography. Participants were randomly allocated to four groups of random frequency stimulation and received a single session of stimulation for 20 min with a current intensity of 2 mA delivered by bilateral periauricular electrode clips. We found that a random pulsed frequency between 6-10 Hz significantly increased the power and coherence in frontal and central areas for the alpha band compared with sham stimulation, while 11-15 Hz tPCS decreased the power for the alpha and theta bandwidth. Our findings corroborate the hypothesis that a random frequency ranging into the boundaries of 6-10 Hz induces changes in the naturally occurring alpha oscillatory activity, providing additional data for further studies with tPCS.